Related Experiment Video
Updated: Sep 29, 2025
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
Evaluation of the TRIP13 level in breast cancer and insights into potential molecular pathways
Jin Lan1, Jingzhan Huang1, Xinyi Tao1
1Department of General Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Abstract:
TRIP13 is a member of the large superfamily of the AAA + ATPase proteins and is associated with a variety of activities. Emerging evidence has shown that TRIP13 may serve as an oncogene. However, the function of TRIP13 in breast cancer (BC) has not yet been elucidated. Here, a variety of bioinformatic tools and laboratory experiments were combined to analyse the expression patterns, prognostic value and functional network of TRIP13 in BC. Multiple databases and immunohistochemistry (IHC) indicated a higher TRIP13 expression in BC tissue compared with normal tissue. TRIP13 was highly expressed in lung metastatic lesions compared with primary tumours in a 4T1 cell implantation BALB/c mouse model of BC. Kaplan-Meier plots also revealed that high TRIP13 expression correlated with poor survival in patients with BC. Furthermore, gene set enrichment analysis revealed that TRIP13 was primarily enriched in the signalling pathway of PI3K-AKT-mTOR. Suppressing TRIP13 could inhibit the expression of related genes, as well as the proliferation and migration of BC cell. Finally, 10 hub genes with a high score of connectivity were filtered from the protein-protein interaction (PPI) network, including MAD2L1, CDC20, CDC5L, CDK1, CCNA2, BUB1B, RAD51, SPO11, KIF11 and AURKB. Thus, TRIP13 may be a promising prognostic biomarker and an effective therapeutic target for BC.
Insights
Thyroid hormone receptor interactor 13 (TRIP13) is upregulated in breast cancer (BC), correlating with poor survival. Targeting TRIP13 may offer a new therapeutic strategy for BC patients.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Thyroid hormone receptor interactor 13 (TRIP13), an AAA+ ATPase, is implicated as an oncogene.
- The specific role of TRIP13 in breast cancer (BC) remains largely uncharacterized.
Purpose of the Study:
- To investigate the expression patterns, prognostic significance, and functional network of TRIP13 in breast cancer.
- To evaluate TRIP13 as a potential diagnostic biomarker and therapeutic target for BC.
Main Methods:
- Bioinformatic analyses utilizing multiple databases.
- Immunohistochemistry (IHC) for protein expression assessment.
- In vitro experiments including cell proliferation and migration assays.
- Protein-protein interaction (PPI) network construction and hub gene identification.
Main Results:
- TRIP13 expression is significantly higher in BC tissues than in normal tissues.
- Elevated TRIP13 levels correlate with poor patient survival and are pronounced in lung metastatic lesions.
- TRIP13 is enriched in the PI3K-AKT-mTOR signaling pathway.
- Downregulation of TRIP13 inhibits BC cell proliferation and migration.
- Ten hub genes (e.g., MAD2L1, CDC20, CDK1) were identified in the TRIP13-associated PPI network.
Conclusions:
- TRIP13 is a promising prognostic biomarker for breast cancer.
- TRIP13 represents a potential therapeutic target for breast cancer treatment.
